Japan's Longevity Science Takes a "Historic Step" in Macau: Asian Institute of Longevity and Innovation Signs Strategic Partnership with MTMC

Asian Institute of Longevity and Innovation, International & Health Medical Innovation Special Reporting Team, Distributed on May 22, 2026

■ Delegation on the International Stage Hosted by MUST

As the world rapidly enters a fully-fledged "Longevity Era", the Asian Institute of Longevity and Innovation (AILI), which unifies Japan's longevity medical and scientific technologies, announced a series of significant achievements at the 2026 "Belt and Road" Great Health International Forum (hosted by the Macau University of Science and Technology Foundation and the Macau Translational Medicine Center, with cooperation from Springer Nature) currently being held in the Macau Special Administrative Region.

The institute dispatched a formidable seven-member delegation led by Chairman Toshihiro Hirosaki. The team included Takeo Kawamura, a founder of the Japan-Macau Greater Bay Area Friendship Parliamentarian League and board member; Asami Sakamoto, a board member dedicated to international affairs; Yukiyasu Sano, head of the NMN division; Dr. Hao Tian, researching molecular hydrogen and telomeres; Liang Guo, a fasting research expert; and Hachiro Sugimoto, a specially appointed scientist and inventor of the world's first Alzheimer's drug "Aricept" (President of Nagoya Aoi University and Visiting Professor at Doshisha University Graduate School). This lineup brought together leading figures from the industrial, policy, and scientific sectors.

[Photo 0] The Asian Institute of Longevity and Innovation delegation. In front of the forum's official banner (Wynn Palace, Macau, May 2026).

The forum took place over four days, from May 19 to 22. Hosted by the Macau University of Science and Technology Foundation and the Macau Translational Medicine Center, and supported by Springer Nature, it represents Macau's premier platform for international medical exchange, backed by various Macau SAR government bureaus, the Science and Technology Development Fund, and the Health Bureau.

[Photo 1] Dr. Sugimoto of the Asian Institute of Longevity and Innovation delegation. In front of the forum's official banner (Wynn Palace, Macau, May 2026).

■ Signing Ceremony Executed: Strategic Partnership with Macau Translational Medicine Center Officially Launched

The most prominent highlight of the forum was the official signing of a strategic cooperation agreement between the Asian Institute of Longevity and Innovation and the Macau Translational Medicine Center (MTMC). Representing the delegation, Chairman Toshihiro Hirosaki signed the agreement with representatives from MTMC, officially commencing a new collaborative relationship in the fields of longevity medicine, anti-aging medicine, and health science technology. The ceremony was attended by Chairman Hirosaki, Board Member Asami Sakamoto, and Board Member Takeo Kawamura, alongside a total of 24 experts with profound expertise in medical, health, and life sciences, forming a large-scale and highly international assembly.

To understand the significance of this agreement, it is necessary to first grasp the historical context of the "Longevity Era". Longevity is no longer merely an individual concern; it is evolving into a global national priority deeply intertwined with social structure, economic development, and national governance. The "Healthy China Strategy" and the "Belt and Road" Health Community promoted by China provide new directions for the global health industry within this very context.

As one of the world's leading countries in longevity, Japan has spent years tackling the challenge of "how to achieve a healthy, high-quality 100-year life". The results have crystalized into a systematized "Longevity Society Solution", encompassing precision health screenings and early cancer detection, comprehensive management of chronic diseases, regenerative and functional medicine, constitution improvement through traditional Chinese medicine, scientific supplement utilization, sleep and mental health management, and community-based health operations. Such Japanese expertise highly aligns with the "Healthy China Strategy" and aging-response strategies, and this agreement serves precisely as a bridge between them.

Under the agreement, both parties will collaboratively promote the practical application of longevity medical technologies, anti-aging medicine, regenerative medicine, precision nutritional management, chronic disease management, advanced membership-based medical services, the international deployment of health science technologies, the modernization of traditional Chinese medicine, and digital health. Among these, the immediate top priorities set to materialize include the establishment of the Macau International Longevity Clinic Demonstration Center, the opening of specialized anti-aging outpatient services, and the local introduction of regenerative medical technologies.

The role Macau plays in this strategy is decisive. It possesses unique institutional advantages born from the "One Country, Two Systems" policy, direct access to the massive market of the Guangdong-Hong Kong-Macau Greater Bay Area, and a cultural and diplomatic network reaching 18 Portuguese-speaking countries and regions. With this threefold strength, Macau serves as an irreplaceable strategic gateway for expanding Japan's longevity technologies across all of Asia.

[Photo 2] The moment Chairman Toshihiro Hirosaki (right) and the MTMC representative (left) sign the agreement. The screen behind them displayed the text "Macau Translational Medicine Center - Asian Institute of Longevity and Innovation Signing Ceremony" (May 20, 2026).

[Photo 3] A commemorative photo holding the agreements after the signing ceremony. A long-term strategic partnership between the two parties was officially established.

■ Inventor of the World's First Alzheimer's Drug Takes the Stage: Pioneering a Trillion-Scale Brain Health Market with "Bacopa x NMN"

At the forum, specially appointed scientist Hachiro Sugimoto took the stage alone to globally broadcast cutting-edge research on cognitive anti-aging. His presentation was titled "The New Blue Ocean of Cognitive Anti-Aging: How Bacopa x NMN Will Pioneer a Trillion-Scale Brain Health and Longevity Market".